Literature DB >> 21814039

Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design.

Enrico L Digiammarino1, John E Harlan, Karl A Walter, Uri S Ladror, Rohinton P Edalji, Charles W Hutchins, Marc R Lake, Amy J Greischar, Junjian Liu, Tariq Ghayur, Clarissa G Jakob.   

Abstract

The DVD-Ig (TM) protein is a dual-specific immunoglobulin. Each of the two arms of the molecule contains two variable domains, an inner variable domain and an outer variable domain linked in tandem, each with binding specificity for different targets or epitopes. One area of on-going research involves determining how the proximity of the outer variable domain affects the binding of ligands to the inner variable domain. To explore this area, we prepared a series of DVD-Ig proteins with binding specificities toward TNFα and an alternate therapeutic target. Kinetic measurements of TNFα binding to this series of DVD-Ig proteins were used to probe the effects of variable domain position and linker design on ligand on- and off-rates. We found that affinities for TNFα are generally lower when binding to the inner domain than to the outer domain and that this loss of affinity is primarily due to reduced association rate. This effect could be mitigated, to some degree, by linker design. We show several linker sequences that mitigate inner domain affinity losses in this series of DVD-Ig proteins. Moreover, we show that single chain proteolytic cleavage between the inner and outer domains, or complete outer domain removal, can largely restore inner domain TNFα affinity to that approaching the reference antibody. Taken together, these results suggest that a loss of affinity for inner variable domains in this set of DVD-Ig proteins may be largely driven by simple steric hindrance effects and can be reduced by careful linker design.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21814039      PMCID: PMC3225853          DOI: 10.4161/mabs.3.5.16326

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  9 in total

1.  Structure and flexibility of individual immunoglobulin G molecules in solution.

Authors:  Sara Sandin; Lars-Göran Ofverstedt; Ann-Charlotte Wikström; Orjan Wrange; Ulf Skoglund
Journal:  Structure       Date:  2004-03       Impact factor: 5.006

2.  Improving biosensor analysis.

Authors:  D G Myszka
Journal:  J Mol Recognit       Date:  1999 Sep-Oct       Impact factor: 2.137

3.  Crystal structure of a soluble CD28-Fab complex.

Authors:  Edward J Evans; Robert M Esnouf; Raquel Manso-Sancho; Robert J C Gilbert; John R James; Chao Yu; Janet A Fennelly; Cheryl Vowles; Thomas Hanke; Björn Walse; Thomas Hünig; Poul Sørensen; David I Stuart; Simon J Davis
Journal:  Nat Immunol       Date:  2005-02-06       Impact factor: 25.606

4.  Fragmentation of immunoglobulin G.

Authors:  Sarah M Andrew; Julie A Titus
Journal:  Curr Protoc Cell Biol       Date:  2003-02

Review 5.  Next generation immunotherapeutics--honing the magic bullet.

Authors:  Carrie Enever; Thil Batuwangala; Chris Plummer; Armin Sepp
Journal:  Curr Opin Biotechnol       Date:  2009-08-24       Impact factor: 9.740

6.  Eradication of established tumors in mice by a combination antibody-based therapy.

Authors:  Tomoyasu Uno; Kazuyoshi Takeda; Yuko Kojima; Hirohisa Yoshizawa; Hisaya Akiba; Robert S Mittler; Fumitake Gejyo; Ko Okumura; Hideo Yagita; Mark J Smyth
Journal:  Nat Med       Date:  2006-05-07       Impact factor: 53.440

7.  On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice.

Authors:  P Parham
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

8.  Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules.

Authors:  Chengbin Wu; Hua Ying; Sahana Bose; Renee Miller; Limary Medina; Ling Santora; Tariq Ghayur
Journal:  MAbs       Date:  2009-07-10       Impact factor: 5.857

9.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

Authors:  Chengbin Wu; Hua Ying; Christine Grinnell; Shaughn Bryant; Renee Miller; Anca Clabbers; Sahana Bose; Donna McCarthy; Rong-Rong Zhu; Ling Santora; Rachel Davis-Taber; Yune Kunes; Emma Fung; Annette Schwartz; Paul Sakorafas; Jijie Gu; Edit Tarcsa; Anwar Murtaza; Tariq Ghayur
Journal:  Nat Biotechnol       Date:  2007-10-14       Impact factor: 54.908

  9 in total
  21 in total

1.  A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.

Authors:  Gregory L Moore; Cristina Bautista; Erik Pong; Duc-Hanh T Nguyen; Jonathan Jacinto; Araz Eivazi; Umesh S Muchhal; Sher Karki; Seung Y Chu; Greg A Lazar
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  High-resolution mass spectrometry confirms the presence of a hydroxyproline (Hyp) post-translational modification in the GGGGP linker of an Fc-fusion protein.

Authors:  Chris Spahr; Kannan Gunasekaran; Kenneth W Walker; Stone D-H Shi
Journal:  MAbs       Date:  2017-05-16       Impact factor: 5.857

Review 3.  Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

Authors:  Christian Klein; Claudio Sustmann; Markus Thomas; Kay Stubenrauch; Rebecca Croasdale; Jürgen Schanzer; Ulrich Brinkmann; Hubert Kettenberger; Jörg T Regula; Wolfgang Schaefer
Journal:  MAbs       Date:  2012-08-27       Impact factor: 5.857

4.  Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule.

Authors:  Clarissa G Jakob; Rohinton Edalji; Russell A Judge; Enrico DiGiammarino; Yingchun Li; Jijie Gu; Tariq Ghayur
Journal:  MAbs       Date:  2013-04-02       Impact factor: 5.857

5.  A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.

Authors:  Juergen M Schanzer; Katharina Wartha; Rebecca Croasdale; Samuel Moser; Klaus-Peter Künkele; Carola Ries; Werner Scheuer; Harald Duerr; Sandra Pompiati; Jan Pollman; Jan Stracke; Wilma Lau; Stefan Ries; Ulrich Brinkmann; Christian Klein; Pablo Umana
Journal:  J Biol Chem       Date:  2014-05-19       Impact factor: 5.157

6.  CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.

Authors:  Anke Steinmetz; François Vallée; Christian Beil; Christian Lange; Nicolas Baurin; Jochen Beninga; Cécile Capdevila; Carsten Corvey; Alain Dupuy; Paul Ferrari; Alexey Rak; Peter Wonerow; Jochen Kruip; Vincent Mikol; Ercole Rao
Journal:  MAbs       Date:  2016-03-16       Impact factor: 5.857

7.  Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.

Authors:  Robert J Benschop; Chi-Kin Chow; Yu Tian; James Nelson; Barbra Barmettler; Shane Atwell; David Clawson; Qing Chai; Bryan Jones; Jon Fitchett; Stacy Torgerson; Yan Ji; Holly Bina; Ningjie Hu; Mahmoud Ghanem; Joseph Manetta; Victor J Wroblewski; Jirong Lu; Barrett W Allan
Journal:  MAbs       Date:  2019-06-10       Impact factor: 5.857

8.  A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.

Authors:  Ingo Schubert; Domenica Saul; Stefanie Nowecki; Andreas Mackensen; Georg H Fey; Fuat S Oduncu
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

9.  Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.

Authors:  Ryan B Craig; Christopher M Summa; Miriam Corti; Seth H Pincus
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

Review 10.  Biology drives the discovery of bispecific antibodies as innovative therapeutics.

Authors:  Siwei Nie; Zhuozhi Wang; Maria Moscoso-Castro; Paul D'Souza; Can Lei; Jianqing Xu; Jijie Gu
Journal:  Antib Ther       Date:  2020-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.